ClinicalTrials.gg

Leukemia, Myeloid, Acute clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 3,669 studies for Leukemia, Myeloid, Acute across more than 10 countries. 817 are recruiting or about to start. 2,597 of them are mainly about Leukemia, Myeloid, Acute (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its 7 narrower conditions too, such as Leukemia, Monocytic, Acute: 3,787 studies, 832 open.

ClinicalTrials.gov finds 4,308 studies for Leukemia, Myeloid, Acute. How that becomes 3,668 here

This page counts the studies the registry files under Leukemia, Myeloid, Acute, and those it files under no condition that list Leukemia, Myeloid, Acutethemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 15, 2026. How condition pages count

  1. 4,308Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −115Filed under a narrower condition, counted on its own pageLeukemia, Promyelocytic, Acute 68 · Leukemia, Mast-Cell 23 · Leukemia, Monocytic, Acute 14 · Leukemia, Megakaryoblastic, Acute 4 · Leukemia, Eosinophilic, Acute 4 · Leukemia, Erythroblastic, Acute 1
  3. −123List Leukemia, Myeloid, Acute as a condition, but the registry did not file them under itMost often written as “Secondary Acute Myeloid Leukemia” (20), “Recurrent Childhood Acute Myeloid Leukemia” (19), and “Acute Myeloid Leukemia in Remission” (19). The registry filed them under other conditions only, most often Precursor Cell Lymphoblastic Leukemia-Lymphoma (44) and Myelodysplastic Syndromes (39).
  4. −402Match it another way198 name it in the title, 73 in a keyword, and 131 by a synonym or other text the search reads.
  5. 3,668The count on this page75 of them list Leukemia, Myeloid, Acute in their own words; the registry filed them under no condition.

Status

Completed
1,597
Recruiting
625
Terminated
538
Status unknown
307
Active, not recruiting
224
Not yet recruiting
166

Phase

Phase 2
1,596
Phase 1
1,500
Phase 3
337
Early Phase 1
55
Phase 4
41

Where

United States
2,137
China
473
France
341
Germany
282
Italy
229
Canada
205

Who develops what

Add Leukemia, Myeloid, Acute to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 87 programs from 47 companies, 72 with this as their studies’ main aim; 18 with a live phase 3 study; 15 primary completions in the next 12 months. Compare Kyowa Kirin, Johnson & Johnson and Beijing Biotech here →

Stage, biomarker and line of therapy are not read yet: these programs are in development here, not all in the same competitive position.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
AzacitidineRecent, repeated
Evidence
  • NCT07925190 · InnoCare Pharma Limited · Phase 3 · live · background · “Azacitidine (AZA)” · registered Oct 2026
  • NCT07743112 · Maxinovel Pty., Ltd. · Phase 2 · live · background · “Azacitidine” · registered Jul 2026
  • NCT07770698 · BeOne Medicines · Phase 2 · live · background · “Azacitidine” · registered May 2026
  • NCT07581002 · AbbVie · Phase 3 · live · background · “Azacitidine” · registered May 2026
  • NCT06852222 · Johnson & Johnson · Phase 3 · live · background · “Azacitidine (AZA)” · registered Feb 2025
Bristol-Myers Squibb29% of its industry studiesUS: off-patent, 11 generics marketedEU: off-patent, 4 generics authorized1212 studies
venetoclaxRecent, repeated
Evidence
  • NCT07925190 · InnoCare Pharma Limited · Phase 3 · live · comparator · “Venetoclax” · registered Oct 2026
  • NCT07743112 · Maxinovel Pty., Ltd. · Phase 2 · live · background · “Venetoclax” · registered Jul 2026
  • NCT06852222 · Johnson & Johnson · Phase 3 · live · background · “Venetoclax (VEN)” · registered Feb 2025
  • NCT06563804 · Servier Bio-Innovation LLC · Phase 2 · background · “Venetoclax” · registered Aug 2024
  • NCT06508489 · Sanofi · Phase 2 · background · “venetoclax” · registered Jun 2024
AbbVie64% of its industry studiesUS: AbbVie (FDA 2016)EU: AbbVie (EMA 2016)1212 studies
Antineoplastic AgentsRecent, repeated
Evidence
  • NCT06578247 · Daiichi Sankyo · Phase 3 · live · background · “Chemotherapy” · registered Aug 2024
  • NCT05886491 · Takeda · Phase 2 · background · “Chemotherapy Agents” · registered May 2023
  • NCT05876832 · Shijiazhuang Yiling Pharmaceutical Co. Ltd · Phase 3 · live · comparator · “Salvage Chemotherapy” · registered May 2023
  • NCT04716114 · CSPC Pharmaceutical Group Limited · Phase 3 · live · comparator · “Salvage Chemotherapy” · registered Dec 2020
  • NCT03512197 · Novartis · Phase 3 · background · “Chemotherapy” · registered Mar 2018
—33 studies
fludarabineRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT07157514 · Actinium Pharmaceuticals · Phase 3 · live · background · “Fludarabine” · registered Aug 2025
  • NCT06680752 · ARCE Therapeutics, Inc. · Phase 2 · live · background · “Fludarabine” · registered Oct 2024
  • NCT04240002 · Astellas Pharma Inc · Phase 2 · background · “fludarabine” · registered Jan 2020
  • NCT04029688 · Hoffmann-La Roche · Phase 2 · background · “Fludarabine” · registered Jul 2019
  • NCT03926624 · Delta-Fly Pharma, Inc. · Phase 3 · comparator · “Fludarabine” · registered Apr 2019
Beijing Biotech18% of its industry studies22 studies
posaconazoleRecent, repeated
Evidence
  • NCT07719348 · Servier · Phase 2 · live · background · “Posaconazole” · registered Jul 2026
  • NCT07155226 · AstraZeneca · Phase 2 · live · background · “Posaconazole” · registered Aug 2025
  • NCT04771130 · BeOne Medicines · Phase 2 · live · background · “Posaconazole” · registered Feb 2021
  • NCT03760445 · Novartis · Phase 2 · background · “posaconazole” · registered Nov 2018
Merck & Co., Inc88% of its industry studiesUS: off-patent, 17 generics marketedEU: off-patent, 2 generics authorized22 studies
CyclophosphamideRecent, repeated
Evidence
  • NCT07157514 · Actinium Pharmaceuticals · Phase 3 · live · background · “Cyclophosphamide” · registered Aug 2025
  • NCT06680752 · ARCE Therapeutics, Inc. · Phase 2 · live · background · “Cyclophosphamide” · registered Oct 2024
  • NCT04029688 · Hoffmann-La Roche · Phase 2 · background · “Cyclophosphamide” · registered Jul 2019
  • NCT03860844 · Sanofi · Phase 2 · background · “Cyclophosphamide” · registered Feb 2019
  • NCT03699475 · Bellicum Pharmaceuticals · Phase 3 · comparator · “Cyclophosphamide” · registered Oct 2018
Hoffmann-La Roche13% of its industry studiesUS: off-patent, 12 generics marketed22 studies

24 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
FLT3 Inhibitor XY0206☆ Track1 live phase-3 study: NCT05876832Shijiazhuang Yiling Pharmaceutical Co. Ltd
venetoclaxApproved: US 2016 · EU 2016☆ Track2 live phase-3 studies: NCT02993523, NCT03844048AbbVie
Anti-CD33 Antibody-drug Conjugate BL-M11D1☆ Track1 live phase-3 study: NCT07255872Sichuan Biokin Pharmaceutical Co., Ltd.
Cytarabine☆ Track1 live phase-3 study: NCT07255872Sichuan Biokin Pharmaceutical Co., Ltd.
DaunorubicinApproved: US☆ Track1 live phase-3 study: NCT07255872Sichuan Biokin Pharmaceutical Co., Ltd.

The 5 in phase 3 with the nearest primary completion, of 87 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (15)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Dec 2026 est.SEL-120, romaciclib, silevertinib · Ryvu Therapeutics SA · Phase 2 main aimstudied with ruxolitinibNCT06987058 RVU120 Rollover Study — primary endpoint: Incidence of Adverse Events (Safety and Tolerability) · 14 enrolled
  • 1 Dec 2026 est.Bcl-2 Inhibitor LOXO-338 · Fosun Pharma · Phase 2 main aimNCT06858618 FCN-338 in Combination With Azacitidine or Chemotherapy in Myeloid Neoplasms — primary endpoint: Incidence of DLT · 47 enrolled
  • Feb 2027 est.pivekimab sunirine · AbbVie · Phase 2 main aimstudied with Azacitidinestudied with venetoclaxNCT04086264 IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia — primary endpoint: Safety and Tolerability · 218 enrolled

12 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Leukemia, Myeloid, Acute studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Antimetabolites 150 open · Alkylating agents 44 open · Tyrosine kinase inhibitors (TKIs) 43 open · Calcineurin inhibitors 11 open · HDAC inhibitors 11 open

Coming up

307studies finish main data collection within a year22 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger. 145 (23%) take children under 18. 2 (<1%) are for women only and 0 (0%) for men only; 29 (5%) take healthy volunteers.

Recruiting studies that take each age, of 625
AgeWomenMen
10100 (16%)100 (16%)
18579 (93%)578 (92%)
30545 (87%)544 (87%)
40536 (86%)535 (86%)
50537 (86%)536 (86%)
65536 (86%)534 (85%)
75462 (74%)460 (74%)
85387 (62%)385 (62%)

Across all 3,669 studies, recruiting or not: 35% stop at 75 or younger and 21% at 65; 25% take children; <1% are for women only and <1% for men only; 3% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Leukemia, Myeloid, Acute studies take

Of 491 phase 1 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 49 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 149 mo31–77 · 491 studies40 mo29–62 · 183 studies52 mo32–89 · 308 studies
Phase 1/273 mo48–106 · 226 studies73 mo45–91 · 92 studies76 mo49–110 · 134 studies
Phase 260 mo38–104 · 443 studies39 mo33–55 · 57 studies67 mo40–108 · 386 studies
Phase 2/366 mo37–86 · 31 studies——
Phase 374 mo39–99 · 121 studies42 mo30–62 · 43 studies87 mo66–111 · 78 studies
Interventional, no phase47 mo25–123 · 139 studies—49 mo26–128 · 132 studies
Observational54 mo36–154 · 160 studies—66 mo41–234 · 128 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 19, 2026.

Newly registered14

Show 9 more

Studies

Recruiting first, then most recently updated. Showing 50 of 3,669. Browse all 3,669 → or search them.